Safety and Efficacy of Dexamethasone Intravitreal Implant Given Either First-Line or Second-Line in Diabetic Macular Edema
Andrea Taloni, Giulia Coco, Davide Rastelli, Giacinta Buffon, Vincenzo Scorcia, Giuseppe Giannaccare · 2023
Read Safety and Efficacy of Dexamethasone Intravitreal Implant Given Either First-Line or Second-Line in Diabetic Macular Edema by Andrea Taloni, Giulia Coco, Davide Rastelli, Giacinta Buffon, Vincenzo Scorcia, Giuseppe Giannaccare (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10725633.txt.
Description
Andrea Taloni and co-authors review a steroid eye implant for diabetic swelling in a 2023 paper. Fluid in the central retina is a top cause of vision loss in working-age diabetics. The slow-release dexamethasone implant calms inflammation and lasts longer than standard injections, but it can raise eye pressure and cloud the lens.
The review weighs when to use it first: patients who cannot take the standard drugs, eyes with strong inflammation signs, eyes with artificial lenses, and eyes after vitrectomy. Switching non-responders and combining therapies also feature. Readers get a placement guide for this implant.
Catalog record
| CREATOR | Andrea Taloni, Giulia Coco, Davide Rastelli, Giacinta Buffon, Vincenzo Scorcia, Giuseppe Giannaccare |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |